Doravirine: a review

Curr Opin HIV AIDS. 2018 Jul;13(4):308-314. doi: 10.1097/COH.0000000000000471.


Purpose of review: The current review addresses the role of doravirine (DOR), a novel once-daily nonnucleoside reverse transcriptase inhibitor (NNRTI) in first-line therapy at a time in which multiple options are available, and issues of antiviral efficacy, safety, simplicity and cost are critical to make informed decisions.

Recent findings: DOR combination regimens have been tested in two large randomized double-blinded clinical trials in treatment-naïve patients, showing noninferiority to ritonavir-boosted darunavir-based and efavirenz (EFV)-based regimens. The main features of DOR are reviewed in this report including its antiviral activity, genetic barrier to resistance, safety, once-daily dosing and coformulation in a single tablet with tenofovir disoproxil fumarate and lamivudine. DOR pharmacokinetics and drug-drug interactions are also reviewed as DOR can be given without food restriction and has no interaction with proton pump inhibitors. DOR has shown a superior safety profile than EFV regarding neuropsychiatric and cutaneous adverse events. DOR is currently being investigated in treatment-experienced patients and in those with transmitted NNRTI drug resistance.

Summary: DOR is a promising new NNRTI that could become the preferred drug in its class for treatment initiation. DOR has shown excellent antiviral activity in treatment-naïve patients, a better safety profile than EFV and a low potential for drug-drug interactions.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / chemistry
  • HIV Infections / drug therapy*
  • Humans
  • Pyridones / administration & dosage*
  • Pyridones / adverse effects
  • Pyridones / chemistry
  • Randomized Controlled Trials as Topic
  • Reverse Transcriptase Inhibitors / administration & dosage*
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / chemistry
  • Triazoles / administration & dosage*
  • Triazoles / adverse effects
  • Triazoles / chemistry


  • Anti-HIV Agents
  • Pyridones
  • Reverse Transcriptase Inhibitors
  • Triazoles
  • doravirine